Search research articles
Contact Us
Filters
Showing results (481-490 of 520) with videos related to
Page
of 52
Sort By:
Hypertension (Dallas, Tex. : 1979)
|
September 28, 2020
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices
Matthew A Sparks, Andrew M South, Andrew D Badley, et al.
Journal of the American College of Cardiology
|
February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Douglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of the American Heart Association
|
November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF
Leanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
July 25, 2018
Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial
Daniel E Weiner, Meyeon Park, Hocine Tighiouart, et al.
Circulation. Heart Failure
|
December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection Fraction
Pooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
Circulation
|
January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
Abhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
Circulation
|
November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
Marc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Journal of Heart Failure
|
February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial
João Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure
|
December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF
Xiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure
|
August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF
Senthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Page
of 52
Search research articles
Search
Showing results (481-490 of 520) with videos related to
Sort By:
Page
of 52
Hypertension (Dallas, Tex. : 1979)
|
September 28, 2020
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices
Matthew A Sparks, Andrew M South, Andrew D Badley, et al.
Journal of the American College of Cardiology
|
February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Douglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of the American Heart Association
|
November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF
Leanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
July 25, 2018
Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial
Daniel E Weiner, Meyeon Park, Hocine Tighiouart, et al.
Circulation. Heart Failure
|
December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection Fraction
Pooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
Circulation
|
January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
Abhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
Circulation
|
November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
Marc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Journal of Heart Failure
|
February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial
João Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
European Journal of Heart Failure
|
December 15, 2024
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF
Xiaowen Wang, Orly Vardeny, Brian Claggett, et al.
European Journal of Heart Failure
|
August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF
Senthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Page
of 52